Kingsbury, Daniel J <br/><br/>
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.  [electronic resource] 

 -  Clinical rheumatology  2014 
 - 1433-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1434-9949 
<br/><br/><label>Standard No.: </label>10.1007/s10067-014-2498-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antirheumatic Agents--adverse effects<br/>Arthritis, Juvenile--blood<br/>Biomarkers--blood<br/>C-Reactive Protein--metabolism<br/>Child, Preschool<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Europe<br/>Female<br/>Humans<br/>International Cooperation<br/>Male<br/>Methotrexate--therapeutic use<br/>Treatment Outcome<br/>United States